Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)
Orphan Drug Cold Chain RequiredFDA Approved
Description
Botulism Antitoxin Heptavalent is a sterile solution of equine immunoglobulin G (IgG) containing antibodies against botulinum toxin types A through G. It is indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin in adults and pediatric patients. The antitoxin neutralizes circulating toxin and prevents progression of paralysis.
Indications & Therapeutic Use
iatrogenic botulism, foodborne botulism, wound botulism, infant botulism
Linked Diseases:
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)
| Generic Name | Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) |
| Brands | 1 brand available |
| Active Ingredient | Botulism Antitoxin Heptavalent (Equine) |
| Drug Class | iatrogenic botulism |
| Manufacturer | Emergent BioSolutions |
| Dosage Forms | IV infusion, 20-100 mL vial |
| Medical Code | J06AA04 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 2 days |
| Reg. Status | FDA Approved |
| Countries | 1 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes